CKPT Depositi SEC - Checkpoint Therapeutics, Inc.- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

LEI	549300NTOG3NRUKVKI74
CIK	1651407

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Checkpoint Therapeutics, Inc.

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

June 9, 2025	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38128 CHECKPOINT THERAPEUTICS, INC. (Exact name of registrant as specifi
May 30, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-216856 No. 333-221488 No. 333-251000 No. 333-268740 No. 333-275643 No. 333-279716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333- 216856 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-221488 Post-E
May 30, 2025	POS AM	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-270474 No. 333-270843 No. 333-271171 No. 333-275644 No: 333-278397 No. 333-281650 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270474 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270843 Post-Ef
May 30, 2025	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commiss
May 30, 2025	EX-3.1	CHECKPOINT THERAPEUTICS, INC. ARTICLE 1 OFFICES   Exhibit 3.1   BYLAWS   OF   CHECKPOINT THERAPEUTICS, INC.   *****   ARTICLE 1 OFFICES   Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware.   Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directo
May 30, 2025	POS AM	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-270474 No. 333-270843 No. 333-271171 No. 333-275644 No: 333-278397 No. 333-281650 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270474 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270843 Post-Ef
May 30, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-216856 No. 333-221488 No. 333-251000 No. 333-268740 No. 333-275643 No. 333-279716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333- 216856 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-221488 Post-E
May 30, 2025	POS AM	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-270474 No. 333-270843 No. 333-271171 No. 333-275644 No: 333-278397 No. 333-281650 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270474 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270843 Post-Ef
May 30, 2025	POS AM	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-270474 No. 333-270843 No. 333-271171 No. 333-275644 No: 333-278397 No. 333-281650 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270474 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270843 Post-Ef
May 30, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-216856 No. 333-221488 No. 333-251000 No. 333-268740 No. 333-275643 No. 333-279716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333- 216856 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-221488 Post-E
May 30, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-216856 No. 333-221488 No. 333-251000 No. 333-268740 No. 333-275643 No. 333-279716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333- 216856 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-221488 Post-E
May 30, 2025	POS AM	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-270474 No. 333-270843 No. 333-271171 No. 333-275644 No: 333-278397 No. 333-281650 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270474 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270843 Post-Ef
May 30, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-216856 No. 333-221488 No. 333-251000 No. 333-268740 No. 333-275643 No. 333-279716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333- 216856 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-221488 Post-E
May 30, 2025	POS AM	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-270474 No. 333-270843 No. 333-271171 No. 333-275644 No: 333-278397 No. 333-281650 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270474 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-270843 Post-Ef
May 30, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 No. 333-216856 No. 333-221488 No. 333-251000 No. 333-268740 No. 333-275643 No. 333-279716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333- 216856 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-221488 Post-E
May 30, 2025	EX-99.1	CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of April 23, 2025 (this “Agreement”), is entered into by and among Sun Pharmaceutical Industries, Inc., a Delaware corporation (“Parent”), and Equiniti Trust Company, LLC (the “Rights Agent”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Merger
May 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Checkpoint Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Checkpoint Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commiss
May 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Checkpoint Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Checkpoint Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commiss
May 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐TRANSITION REPORT PUR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-
May 13, 2025	EX-99.1	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates UNLOXCYTTM (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Spe Exhibit 99.1 Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates UNLOXCYTTM (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 Waltham, MA – May 13, 2025 – Checkpoint Therapeutics, Inc. (
April 23, 2025	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act Of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act Of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
April 15, 2025	EX-2.1	Amendment to the Agreement and Plan of Merger, dated as of April 14, 2025, by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc., and Snoopy Merger Sub, Inc. Exhibit 2.1 AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER This AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of April 14, 2025 (the “Amendment Date”), is entered into by and among Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), Sun Pharmaceutical Industries, Inc., a Delaware corporation (“Parent”), and Snoopy Merger Sub, Inc., a Delaware corporat
April 15, 2025	EX-2.1	Amendment to the Agreement and Plan of Merger, dated as of April 14, 2025, by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc., and Snoopy Merger Sub, Inc. Exhibit 2.1 AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER This AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of April 14, 2025 (the “Amendment Date”), is entered into by and among Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), Sun Pharmaceutical Industries, Inc., a Delaware corporation (“Parent”), and Snoopy Merger Sub, Inc., a Delaware corporat
April 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Checkpoint Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commi
April 15, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Checkpoint Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commi
April 14, 2025	PREM14A	PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION, DATED APRIL 14, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act Of 1934 TABLE OF CONTENTS PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION, DATED APRIL 14, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 14, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Schedule 14A (Form Type) Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Checkpoint Therapeutics, Inc.
March 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2025 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2025 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissio
March 28, 2025	EX-4.6	Description of Securities of Checkpoint Therapeutics, Inc. * Exhibit 4.6 DESCRIPTION OF SECURITIES When used herein, the terms “we,” “our,” and “us” refer to Checkpoint Therapeutics, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of Checkpoint capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
March 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-38128 CHECKP
March 28, 2025	EX-99.1	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates UNLOXCYTTM (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Exhibit 99.1 Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates UNLOXCYTTM (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Waltham, MA – March 28, 2025 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company,
March 28, 2025	EX-10.46	Change in Control Severance Plan. * Exhibit 10.46 checkpoint therapeutics, INC. CHANGE IN CONTROL SEVERANCE PLAN April 26, 2022 Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted this Change in Control Severance Plan (the “Plan”), dated as of April 26, 2022, and effective upon the consummation of a Change in Control (as defined herein), for the benefit of its employees, on the terms and conditions her
March 28, 2025	EX-19.1	Insider Trading Plan. * Exhibit 19.1 FORTRESS BIOTECH, INC. AND SUBSIDIARIES INSIDER TRADING POLICY January 22, 2024 PERSONS COVERED This Insider Trading Policy applies to Fortress Biotech, Inc. (“Fortress”) and each of its publicly traded and private subsidiaries in which Fortress has a 50% or greater ownership interest or otherwise has a minority economic interest but majority voting interest. Fortress and each such su
March 10, 2025	EX-10.1	Support Agreement, dated as of March 9, 2025, by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc., and Fortress Biotech, Inc.   Exhibit 10.1   SUPPORT AGREEMENT   This Support Agreement (this “Agreement”) is made and entered into as of March 9, 2025, by and among Sun Pharmaceutical Industries, Inc., a Delaware corporation (“Parent”), Fortress Biotech, Inc., a Delaware corporation (the “Stockholder”), and Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”).   Recitals   A.            Concurrently with th
March 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2025 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2025 Checkpoint Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commis
March 10, 2025	EX-10.1	Support Agreement, dated as of March 9, 2025, by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc., and Fortress Biotech, Inc.   Exhibit 10.1   SUPPORT AGREEMENT   This Support Agreement (this “Agreement”) is made and entered into as of March 9, 2025, by and among Sun Pharmaceutical Industries, Inc., a Delaware corporation (“Parent”), Fortress Biotech, Inc., a Delaware corporation (the “Stockholder”), and Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”).   Recitals   A.            Concurrently with th
March 10, 2025	EX-4.1	Letter agreement, dated as of March 9, 2025, by and between Checkpoint Therapeutics, Inc. and Armistice Capital Master Fund Ltd. Exhibit 4.1 Checkpoint Therapeutics, Inc. 95 Sawyer Road, Suite 110 Waltham, MA 02453 March 9, 2025 Armistice Capital Master Fund Ltd. 510 Madison Avenue New York, NY 10022 Re: Warrant Amendment Dear Holder: Reference is hereby made to the warrants to purchase (i) 475,000 shares of common stock of Checkpoint Therapeutics, Inc. (CKPT) (the “Company”), dated as of April 4, 2023, at an initial exerci
March 10, 2025	EX-2.1	Agreement and Plan of Merger, dated as of March 9, 2025, by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc., and Snoopy Merger Sub, Inc. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc. and Snoopy Merger Sub, Inc. Dated as of March 9, 2025 Table of Contents Page Article I THE MERGER 2 Section 1.1 Merger of Merger Sub into the Company 2 Section 1.2 Effect of the Merger 2 Section 1.3 Closing; Effective Time 3 Section 1.4 Certificate of Incorporation and Bylaws; D
March 10, 2025	EX-2.1	Agreement and Plan of Merger, dated as of March 9, 2025, by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc., and Snoopy Merger Sub, Inc. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among Checkpoint Therapeutics, Inc., Sun Pharmaceutical Industries, Inc. and Snoopy Merger Sub, Inc. Dated as of March 9, 2025 Table of Contents Page Article I THE MERGER 2 Section 1.1 Merger of Merger Sub into the Company 2 Section 1.2 Effect of the Merger 2 Section 1.3 Closing; Effective Time 3 Section 1.4 Certificate of Incorporation and Bylaws; D
March 10, 2025	EX-3.1	Bylaw Amendment, dated as of March 9, 2025, filed as Exhibit 3.1 to Form 8-K filed on March 10, 2025 (File No. 001-38128) and incorporated herein by reference. Exhibit 3.1 CHECKPOINT THERAPEUTICS, INC. BYLAW AMENDMENT The Bylaws of Checkpoint Therapeutics, Inc. are hereby amended to add a new Article XII, as set forth below: ARTICLE XII FORUM Unless the corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, (a) the Court of Chancery of the State of Delaware (or, if and only if the Court of Chance
March 10, 2025	EX-99.1	Sun Pharma to Acquire Checkpoint Therapeutics Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma’s global onco-derm fra Exhibit 99.1 Sun Pharma to Acquire Checkpoint Therapeutics Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma’s global onco-derm franchise Will leverage Sun Pharma’s global presence to accelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4
March 10, 2025	EX-99.1	Joint Press Release, dated March 9, 2025. Exhibit 99.1 Sun Pharma to Acquire Checkpoint Therapeutics Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma’s global onco-derm franchise Will leverage Sun Pharma’s global presence to accelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4
March 10, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
March 10, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2025 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2025 Checkpoint Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commis
March 10, 2025	EX-3.1	Bylaws Amendment, dated as of March 9, 2025. Exhibit 3.1 CHECKPOINT THERAPEUTICS, INC. BYLAW AMENDMENT The Bylaws of Checkpoint Therapeutics, Inc. are hereby amended to add a new Article XII, as set forth below: ARTICLE XII FORUM Unless the corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, (a) the Court of Chancery of the State of Delaware (or, if and only if the Court of Chance
March 10, 2025	EX-4.1	Letter Agreement, dated as of March 9, 2025, by and between Checkpoint Therapeutics, Inc. and Armistice Capital Master Fund Ltd., filed as Exhibit 4.1 to Form 8-K filed on March 10, 2025 (File No. 001-38128) and incorporated herein by reference. Exhibit 4.1 Checkpoint Therapeutics, Inc. 95 Sawyer Road, Suite 110 Waltham, MA 02453 March 9, 2025 Armistice Capital Master Fund Ltd. 510 Madison Avenue New York, NY 10022 Re: Warrant Amendment Dear Holder: Reference is hereby made to the warrants to purchase (i) 475,000 shares of common stock of Checkpoint Therapeutics, Inc. (CKPT) (the “Company”), dated as of April 4, 2023, at an initial exerci
January 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2025 Checkpoint Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2025 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissi
January 10, 2025	EX-10.1	Executive Employment Agreement by and between William Garrett Gray and Checkpoint Therapeutics, Inc. dated January 7, 2025, filed as Exhibit 10.1 to Form 8-K filed on January 10, 2025 (File No. 001-38128) and incorporated herein by reference. # Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made and entered into as of January 7, 2025 by and between Checkpoint Therapeutics, Inc. (the “Company”) and William Garrett Gray (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. Recitals WHEREAS, the Com
December 16, 2024	EX-99.1	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYTTM (cosibelimab-ipdl) UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Exhibit 99.1 Checkpoint Therapeutics Announces FDA Approval of UNLOXCYTTM (cosibelimab-ipdl) UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Waltham, MA – December 13, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYTTM (cosibeli
December 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2024 Checkpoint Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commis
November 14, 2024	SC 13G/A	CKPT / Checkpoint Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-ckpt093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 162828206 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐TRANSITION REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number
November 12, 2024	EX-99.1	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 Exhibit 99.1 Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 Waltham, MA – November 12, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financia
November 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 Checkpoint Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commis
October 1, 2024	SC 13D/A	CKPT / Checkpoint Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit
August 28, 2024	CORRESP	August 28, 2024 August 28, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 19, 2024	EX-FILING FEES	Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Checkpoint Therapeutics, Inc.
August 19, 2024	S-3	As filed with the Securities and Exchange Commission on August 19, 2024. As filed with the Securities and Exchange Commission on August 19, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 47-2568632
August 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissi
August 12, 2024	EX-99.1	Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates Exhibit 99.1 Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates Waltham, MA – August 12, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates. James F. Oliviero, Presid
August 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3
July 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2024 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
July 25, 2024	EX-99.1	Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma Exhibit 99.1 Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma · PDUFA goal date of December 28, 2024 set by FDA Waltham, MA – July 25, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food a
July 3, 2024	424B5	1,230,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 4,623,659 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-270843 Prospectus Supplement (to Prospectus dated May 5, 2023) 1,230,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 4,623,659 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 1,230,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), and pre-funded warran
July 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commis
July 3, 2024	EX-99.1	Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab Exhibit 99.1 Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab Waltham, MA – July 2, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”
July 3, 2024	EX-4.1	Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Checkpoint Therapeutics, Inc. Warrant Shares: [] Issue Date:, 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
July 3, 2024	EX-4.3	Form of Placement Agent Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 3, 2024	EX-4.2	Form of Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 3, 2024	EX-10.1	Form of Securities Purchase Agreement, dated as of July 2, 2024, by and between Checkpoint Therapeutics, Inc. and the Purchaser Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 2, 2024, between Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit
July 3, 2024	EX-99.2	Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.2 Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Waltham, MA – July 2, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for t
June 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2024 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
June 24, 2024	EX-99.1	Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission Exhibit 99.1 Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission Waltham, MA – June 24, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) re
May 24, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CHECKPOINT THERAPEUTICS, INC.
May 24, 2024	S-8	As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-2568632 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl
May 17, 2024	SC 13D/A	CKPT / Checkpoint Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit
May 14, 2024	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., filed as Exhibit 3.1 to Form 8-K filed on May 14, 2024 (File No. 001-38128) and incorporated herein by reference. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHECKPOINT THERAPEUTICS, INC. Checkpoint Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That the Corporation’s original Certificate of Incorporation was filed on
May 14, 2024	EX-10.1	Amendment to Executive Employment Agreement by and between James F. Oliviero III and Checkpoint Therapeutics, Inc. dated September 27, 2016, filed as Exhibit 10.1 to Form 8-K filed on October 3, 2016 (File No. 000-55506) and incorporated herein by reference. # Exhibit 10.1 CHECKPOINT THERAPEUTICS, INC. AMENDED AND RESTATED 2015 INCENTIVE PLAN ARTICLE 1 PURPOSE 1.1.      GENERAL. The purpose of the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (the “Plan”) is to promote the success, and enhance the value, of Checkpoint Therapeutics, Inc. (the “Company”), by linking the personal interests of employees, officers, directors and cons
May 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 Checkpoint Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
May 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2024 Checkpoint Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-
May 10, 2024	EX-99.1	Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates Exhibit 99.1 Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates Waltham, MA – May 10, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates. James F. Oliviero, President
May 10, 2024	EX-10.1	Amended and Restarted Non-Employee Directors Compensation Plan.* # Exhibit 10.1 AMENDED & RESTATED CHECKPOINT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTORS COMPENSATION PLAN AMENDED & RESTATED CHECKPOINT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTORS COMPENSATION PLAN ARTICLE 1 PURPOSE 1.1.PURPOSE. The purpose of the Amended and Restated Checkpoint Therapeutics, Inc. Non-Employee Directors Compensation Plan is to attract, retain and compensate highly-qualified individuals
April 3, 2024	CORRESP	April 3, 2024 April 3, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
April 2, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
April 2, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
March 29, 2024	S-3	As filed with the Securities and Exchange Commission on March 29, 2024. As filed with the Securities and Exchange Commission on March 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 47-2568632 (
March 29, 2024	EX-FILING FEES	Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Checkpoint Therapeutics, Inc.
March 22, 2024	EX-10.12_3	Mutual Termination Agreement (Collaboration) by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated September 30, 2023. Exhibit 10.12.3 MUTUAL TERMINATION AGREEMENT This Mutual Termination Agreement (this “Agreement”) is effective as of September 30, 2023 (the “Effective Date”) by and between Checkpoint Therapeutics, Inc., a Delaware corporation with its place of business at 95 Sawyer Road, Suite 110, Waltham, MA 02453 (“CTI”) and TG Therapeutics, Inc., a Delaware corporation with its place of business at 2 Gansevo
March 22, 2024	EX-10.12_2	Mutual Termination Agreement (Sublicense) by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated September 30, 2023. Exhibit 10.12.2 MUTUAL TERMINATION AGREEMENT This Mutual Termination Agreement (this “Agreement”) is effective as of September 30, 2023 (the “Effective Date”) by and between Checkpoint Therapeutics, Inc., a Delaware corporation with its place of business at 95 Sawyer Road, Suite 110, Waltham, MA 02453 (“Checkpoint”) and TG Therapeutics, Inc., a Delaware corporation with its place of business at 2
March 22, 2024	SC 13D/A	CKPT / Checkpoint Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm249605-1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A.
March 22, 2024	EX-99.1	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Exhibit 99.1 Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Waltham, MA – March 22, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights. James F. Oliviero, Preside
March 22, 2024	EX-97.1	Policy Related to Recovery of Erroneously Awarded Compensation. * Exhibit 97.1 CHECKPOINT THERAPEUTICS, INC. INCENTIVE COMPENSATION RECOVERY POLICY 1.0 General. 1.1 Checkpoint Therapeutics, Inc. (the “Company”) has adopted this Policy in accordance with the applicable listing standards of Nasdaq and Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which require listed companies to adopt and comply with a compensation recover
March 22, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
March 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissio
March 22, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-38128 CHECKP
March 22, 2024	EX-4.6	Description of Securities of Checkpoint Therapeutics, Inc. * Exhibit 4.6 DESCRIPTION OF SECURITIES When used herein, the terms “we,” “our,” and “us” refer to Checkpoint Therapeutics, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of Checkpoint capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
March 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commi
March 18, 2024	EX-99.1	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors Exhibit 99.1 Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors Waltham, MA – March 18, 2024 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non
February 14, 2024	SC 13G/A	US1628282063 / CHECKPOINT THERAPEUTICS INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Checkpoint Thera UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Com
January 30, 2024	EX-4.2	Form of Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
January 30, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2024 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Com
January 30, 2024	EX-99.1	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market Exhibit 99.1 Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market WALTHAM, Mass., January 29, 2024 (GLOBE NEWSWIRE) - Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional inves
January 30, 2024	EX-10.1	Form of Securities Purchase Agreement, dated as of January 27, 2024, by and between Checkpoint Therapeutics, Inc. and the Purchaser Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2024, between Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co
January 30, 2024	EX-4.3	Form of Placement Agent Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
January 30, 2024	424B5	1,275,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 6,481,233 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-270843 Prospectus Supplement (to Prospectus dated May 5, 2023) 1,275,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 6,481,233 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 1,275,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), and pre-funded warran
January 30, 2024	EX-4.1	Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Checkpoint Therapeutics, Inc. Warrant Shares: [] Issue Date:, 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Checkpoint Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Comm
December 18, 2023	EX-99.1	U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability Exhibit 99.1 U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab Waltham, MA – December 18, 2023 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.
December 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Checkpoint Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Co
November 21, 2023	CORRESP	November 21, 2023 November 21, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 17, 2023	EX-FILING FEES	Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Checkpoint Therapeutics, Inc.
November 17, 2023	S-3	As filed with the Securities and Exchange Commission on November 17, 2023. As filed with the Securities and Exchange Commission on November 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-2568632 (State or Other Jurisdiction of Incorporation or Organization
November 17, 2023	S-8	As filed with the Securities and Exchange Commission on November 17, 2023 As filed with the Securities and Exchange Commission on November 17, 2023 File No.
November 17, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CHECKPOINT THERAPEUTICS, INC.
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Checkpoint Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commis
November 13, 2023	EX-99.1	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal Exhibit 99.1 Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy of Cancer Waltham, MA – November 13, 2023 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (
October 3, 2023	EX-99.1	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds Exhibit 99.1 Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds Waltham, MA – October 2, 2023 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up
October 3, 2023	EX-4.1	Form of Series A/B common stock purchase warrant, filed as Exhibit 4.1 to Form 8 - K filed on October 3, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 3, 2023	EX-10.1	Inducement Offer to Exercise Warrants Issued in December 2022 and February 2023, filed as Exhibit 10.1 to Form 8-K filed on October 3, 2023 (File No. 001-38128) and incorporated herein by reference. Exhibit 10.1 CHECKPOINT THERAPEUTICS, INC. October 2, 2023 Holder of Warrants Issued in December 2022 and February 2023 Re: Inducement Offer to Exercise Warrants Issued in December 2022 and February 2023 Dear Holder: CHECKPOINT THERAPEUTICS, INC. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase shares of the
October 3, 2023	EX-4.2	Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Checkpoint Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Comm
September 26, 2023	SC 13D/A	US1628282063 / CHECKPOINT THERAPEUTICS INC / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3
August 14, 2023	EX-99.1	Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of Jan Exhibit 99.1 Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results demonstrate substantial increases in complete response rates and continued favorable safety
August 14, 2023	EX-10.1	Amended and Restated Non-Employee Directors Compensation Plan.* # Exhibit 10.1 AMENDED & RESTATED CHECKPOINT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTORS COMPENSATION PLAN AMENDED & RESTATED CHECKPOINT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTORS COMPENSATION PLAN ARTICLE 1 PURPOSE 1.1.PURPOSE. The purpose of the Amended and Restated Checkpoint Therapeutics, Inc. Non-Employee Directors Compensation Plan is to attract, retain and compensate highly-qualified individuals
August 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 Checkpoint Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissi
July 31, 2023	424B5	2,427,186 Shares of Common Stock Pre-Funded Warrants to Purchase up to 809,062 Shares of Common Stock Series A Common Warrants to Purchase up to 3,236,248 Shares of Common Stock Series B Common Warrants to Purchase up to 3,236,248 Shares of Common St Filed Pursuant to Rule 424(b)(5) Registration No. 333-270843 Prospectus Supplement (to Prospectus dated May 5, 2023) 2,427,186 Shares of Common Stock Pre-Funded Warrants to Purchase up to 809,062 Shares of Common Stock Series A Common Warrants to Purchase up to 3,236,248 Shares of Common Stock Series B Common Warrants to Purchase up to 3,236,248 Shares of Common Stock Placement Agent Warrants to P
July 31, 2023	EX-10.1	Securities Purchase Agreement, dated July 28, 2023, between Checkpoint Therapeutics, Inc. and the Purchasers named therein, filed as Exhibit 10.1 to Form 8-K filed on July 31, 2023 (File No. 001-38128) and incorporated herein by reference. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 28, 2023, between Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi
July 31, 2023	EX-4.3	Form of placement agent warrant, filed as Exhibit 4.3 to Form 8 - K filed on July 31, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CHECKPOINT THERAPEUTICS, INC. Warrant Shares: [] Issue Date: July 31, 2023 Initial Exercise Date: July 31, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereina
July 31, 2023	EX-4.1	Form of pre - funded common stock purchase warrant, filed as Exhibit 4.1 to Form 8 - K filed on July 31, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Checkpoint Therapeutics, Inc. Warrant Shares: [] Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
July 31, 2023	EX-4.2	Form of Series A/B common stock purchase warrant, filed as Exhibit 4.2 to Form 8 - K filed on July 31, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.2 [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT CHECKPOINT THERAPEUTICS, INC. Warrant Shares: [] Issue Date:, 2023 Initial Exercise Date: , 2023 THIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se
July 31, 2023	EX-99.1	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Exhibit 99.1 Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) - Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 sh
July 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commis
July 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commis
July 27, 2023	EX-99.1	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma 55% objective response rate; 23% complete response rate in locally advanced Exhibit 99.1 Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma 55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety
July 6, 2023	SC 13D/A	US1628282063 / CHECKPOINT THERAPEUTICS INC / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit
June 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2023 Checkpoint Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2023 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
June 13, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., filed as Exhibit 3.1 to Form 8-K filed on June 13, 2023 (File No. 001-38128) and incorporated herein by reference. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHECKPOINT THERAPEUTICS, INC. Checkpoint Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That the Corporation’s original Certificate of Incorporation was filed on
June 13, 2023	EX-10.1	Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan, filed as Exhibit 10.1 to Form 8 - K filed on June 13, 2023 (File No. 001 - 38128) and incorporated herein by reference. # Exhibit 10.1 CHECKPOINT THERAPEUTICS, INC. AMENDED AND RESTATED 2015 INCENTIVE PLAN ARTICLE 1 PURPOSE 1.1. GENERAL. The purpose of the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (the “Plan”) is to promote the success, and enhance the value, of Checkpoint Therapeutics, Inc. (the “Company”), by linking the personal interests of employees, officers, directors and consultan
May 24, 2023	EX-4.2	Form of Series A/B common stock purchase warrant, filed as Exhibit 4.2 to Form 8 - K filed on May 24, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.2   [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT   CHECKPOINT THERAPEUTICS, INC.   Warrant Shares: [] Issue Date:, 2023       Initial Exercise Date: , 2023   THIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
May 24, 2023	424B5	1,650,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,606,269 Shares of Common Stock Series A Common Warrants to Purchase up to 3,256,269 Shares of Common Stock Series B Common Warrants to Purchase up to 3,256,269 Shares of Common Filed Pursuant to Rule 424(b)(5) Registration No. 333-270843 Prospectus Supplement (to Prospectus dated May 5, 2023) 1,650,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,606,269 Shares of Common Stock Series A Common Warrants to Purchase up to 3,256,269 Shares of Common Stock Series B Common Warrants to Purchase up to 3,256,269 Shares of Common Stock Placement Agent Warrants to
May 24, 2023	EX-99.1	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) - Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggrega
May 24, 2023	EX-4.1	Form of pre - funded common stock purchase warrant, filed as Exhibit 4.1 to Form 8 - K filed on May 24, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.1    PRE-FUNDED COMMON STOCK PURCHASE WARRANT   Checkpoint Therapeutics, Inc.   Warrant Shares: [] Issue Date:, 2023       Initial Exercise Date: , 2023   THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f
May 24, 2023	EX-4.3	Form of placement agent warrant, filed as Exhibit 4.3 to Form 8 - K filed on May 24, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.3    PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT   CHECKPOINT THERAPEUTICS, INC.   Warrant Shares: [] Issue Date: May 25, 2023       Initial Exercise Date: May 25, 2023   THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi
May 24, 2023	EX-10.1	Securities Purchase Agreement, dated May 23, 2023, between Checkpoint Therapeutics, Inc. and the Purchaser named therein, filed as Exhibit 10.1 to Form 8-K filed on May 24, 2023 (File No. 001-38128) and incorporated herein by reference. Exhibit 10.1   SECURITIES PURCHASE AGREEMENT   This Securities Purchase Agreement (this “Agreement”) is dated as of May 23, 2023, between Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).   WHEREAS, subject to the terms and
May 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Checkpoint Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commiss
May 15, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-
May 15, 2023	EX-99.1	Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell car Exhibit 99.1 Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 Waltham, MA – May 15, 2023 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a cl
May 3, 2023	CORRESP	May 3, 2023 May 3, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 3, 2023	CORRESP	May 3, 2023 May 3, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 3, 2023	CORRESP	May 3, 2023 May 3, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 1, 2023	DEF 14A	Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on May 1, 2023 DEF 14A 1 tm232157-2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide
April 21, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) PRE 14A 1 tm232157-1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide
April 19, 2023	SC 13D/A	US1628282063 / CHECKPOINT THERAPEUTICS INC / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit
April 6, 2023	EX-FILING FEES	Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Checkpoint Therapeutics, Inc.
April 6, 2023	S-3	As filed with the Securities and Exchange Commission on April 6, 2023. As filed with the Securities and Exchange Commission on April 6, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 47-2568632 (I
April 4, 2023	EX-4.1	Form of Series A/B common stock purchase warrant, filed as Exhibit 4.1 to Form 8 - K filed on April 4, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 4, 2023	EX-10.1	Securities Purchase Agreement, dated March 30, 2023, between Checkpoint Therapeutics, Inc. and the Purchasers named therein, filed as Exhibit 10.1 to Form 8-K filed on April 4, 2023 (File No. 001-38128) and incorporated herein by reference. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2023, between Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond
April 4, 2023	424B5	1,700,000 Shares of Common Stock 424B5 1 tm2311408d1424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-251005 Prospectus Supplement (to Prospectus dated December 17, 2020) 1,700,000 Shares of Common Stock We are offering 1,700,000 shares of our common stock, par value $0.0001 per share (“Common Stock”) to certain investors pursuant to this prospectus supplement and the accompanying prospectus. Such investors wi
April 4, 2023	EX-99.1	Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) - Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggre
April 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commi
April 4, 2023	EX-4.2	Form of placement agent warrant, filed as Exhibit 4.2 to Form 8 - K filed on April 4, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-38128 CHECKP
March 31, 2023	EX-99.1	Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcino Exhibit 99.1 Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 Waltham, MA – March 30, 2023 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clin
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissio
March 31, 2023	EX-4.6	Description of Securities of Checkpoint Therapeutics, Inc. * Exhibit 4.6 DESCRIPTION OF SECURITIES When used herein, the terms “we,” “our,” and “us” refer to Checkpoint Therapeutics, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of Checkpoint capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
March 24, 2023	EX-4.4	Form of Indenture Exhibit 4.4 Checkpoint therapeutics, inc. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 §311 11.01(f), 16.02 §312 14.02(d), 16.02 (
March 24, 2023	S-3	As filed with the Securities and Exchange Commission on March 24, 2023 As filed with the Securities and Exchange Commission on March 24, 2023 Registration No.
March 24, 2023	EX-FILING FEES	Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Checkpoint Therapeutics, Inc.
March 10, 2023	EX-FILING FEES	Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Checkpoint Therapeutics, Inc.
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Checkpoint Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Commi
March 10, 2023	S-3	As filed with the Securities and Exchange Commission on March 10, 2023. As filed with the Securities and Exchange Commission on March 10, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 47-2568632 (
March 2, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Co
March 2, 2023	EX-99.1	Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA ind Exhibit 99.1 Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting Waltham, MA – March 2, 2023 – Checkpoint Therapeutics, Inc.
February 22, 2023	EX-10.1	Securities Purchase Agreement, dated February 20, 2023, between Checkpoint Therapeutics, Inc. and the Purchaser named therein, filed as Exhibit 10.1 to Form 8-K filed on February 22, 2023 (File No. 001-38128) and incorporated herein by reference. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February , 2023, between Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con
February 22, 2023	EX-4.3	Form of placement agent warrant, filed as Exhibit 4.3 to Form 8 - K filed on February 22, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
February 22, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Co
February 22, 2023	EX-4.1	Form of pre - funded common stock purchase warrant, filed as Exhibit 4.1 to Form 8 - K filed on February 22, 2023 (File No. 001 - 38128) and incorporated herein by reference. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Checkpoint Therapeutics, Inc. Warrant Shares: [] Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
February 22, 2023	EX-4.2	Form of Series A/B common stock purchase warrant, filed as Exhibit 4.2 to Form 8 - K filed on February 22, 2023 (File No. 001 - 38128) and incorporated herein by reference. EX-4.2 3 tm237500d1ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOL
February 22, 2023	EX-99.1	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules EX-99.1 7 tm237500d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WALTHAM, Mass., February 21, 2023 (GLOBE NEWSWIRE) - Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive a
February 22, 2023	424B5	1,180,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 248,572 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-251005 Prospectus Supplement (to Prospectus dated December 17, 2020) 1,180,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 248,572 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 1,180,000 shares of our common stock, par value $0.0001 per share (“Common Stock”) to an investor pur
February 14, 2023	SC 13G	CKPT / Checkpoint Therapeutics Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 13, 2023	SC 13D/A	CKPT / Checkpoint Therapeutics Inc / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.0001 Par Value (Title of Class of Securities) 162828 206 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suit
January 4, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Comm
January 4, 2023	EX-99.1	Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Positive and clinically meaningful pivotal clinical results announc Exhibit 99.1 Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications Waltham, MA – January 4, 2023 – Checkpoint Therapeutics, Inc. (“Checkpoint
December 16, 2022	424B5	950,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 784,105 Shares of Common Stock Series A Common Warrants to Purchase up to 1,734,105 Shares of Common Stock Series B Common Warrants to Purchase up to 1,734,105 Shares of Common Stoc Filed Pursuant to Rule 424(b)(5) Registration No. 333-251005 Prospectus Supplement (to Prospectus dated December 17, 2020) 950,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 784,105 Shares of Common Stock Series A Common Warrants to Purchase up to 1,734,105 Shares of Common Stock Series B Common Warrants to Purchase up to 1,734,105 Shares of Common Stock Placement Agent Warrants
December 16, 2022	EX-99.1	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WALTHAM, Mass., December 15, 2022 (GLOBE NEWSWIRE) - Checkpoint Therapeutics, Inc. (?Checkpoint?) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicate
December 16, 2022	EX-4.2	Form of Series A/B common stock purchase warrant, filed as Exhibit 4.2 to Form 8-K filed on December 16, 2022 (File No. 001-38128) and incorporated herein by reference. Exhibit 4.2 [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT CHECKPOINT THERAPEUTICS, INC. Warrant Shares: [] Issue Date:, 2022 Initial Exercise Date:, 2022 THIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
December 16, 2022	EX-4.1	Form of pre-funded common stock purchase warrant, filed as Exhibit 4.1 to Form 8-K filed on December 16, 2022 (File No. 001-38128) and incorporated herein by reference. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Checkpoint Therapeutics, Inc. Warrant Shares: [] Issue Date:, 2022 Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
December 16, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Checkpoint Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Checkpoint Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38128 47-2568632 (State or other jurisdiction of incorporation) (Co
December 16, 2022	EX-4.3	Form of placement agent warrant, filed as Exhibit 4.3 to Form 8-K filed on December 15, 2022 (File No. 001-38128) and incorporated herein by reference. Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CHECKPOINT THERAPEUTICS, INC. Warrant Shares: [] Issue Date: December 16, 2022 Initial Exercise Date: December 16, 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions
December 16, 2022	EX-10.1	Securities Purchase Agreement, dated December 14, 2022, between Checkpoint Therapeutics, Inc. and the Purchaser named therein, filed as Exhibit 10.1 to Form 8-K filed on December 16, 2022 (File No. 001-38128) and incorporated herein by reference. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 14, 2022, between Checkpoint Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and c
December 9, 2022	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHECKPOINT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 47-2568632 (I.R.S. Employer Identification Number) 95 Sawyer Road, Suite 110 Waltham, MA 02453 (Address, I
December 9, 2022	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CHECKPOINT THERAPEUTICS, INC.
December 5, 2022	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., filed as Exhibit 3.1 to Form 8-K filed on December 5, 2022 (File No. 001-38128) and incorporated herein by reference. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHECKPOINT THERAPEUTICS, INC. Checkpoint Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: FIRST: That the Corporation?s original Certificate of Incorporation
December 5, 2022	EX-10.1	Amendment to Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan, filed as Exhibit 10.1 to Form 8-K on December 5, 2022 (File No. 001-38128) and incorporated herein by reference. # Exhibit 10.1 AMENDMENT TO THE CHECKPOINT THERAPEUTICS, INC. AMENDED AND RESTATED 2015 INCENTIVE PLAN This Amendment to the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (the ?Plan?), is hereby adopted, effective as of the date indicated below. WITNESETH: WHEREAS, Checkpoint Therapeutics, Inc. (the ?Corporation?) maintains the Plan, and the Plan is currently in effect; and
December 5, 2022	EX-99.1	Checkpoint Therapeutics Announces Reverse Stock Split Exhibit 99.1 Checkpoint Therapeutics Announces Reverse Stock Split Waltham, MA ? December 5, 2022 ? Checkpoint Therapeutics, Inc. (?Checkpoint?) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock. Checkpoint expects its common stock to begin trading on a split-ad
December 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commiss
November 14, 2022	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement x Definitive Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Checkpoint Therapeutics, Inc. (Name
November 10, 2022	EX-32._1	Certification of Principal Executive Officer of Checkpoint Therapeutics, Inc. pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated November 10, 2022. Exhibit 32.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, James F. Oliviero, Chief Executive Officer of Checkpoint Therapeutics, Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the
November 10, 2022	EX-31._2	Certification of Principal Financial Officer of Checkpoint Therapeutics, Inc. pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 10, 2022. Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Garrett Gray, certify that: 1. I have reviewed this report on Form 10-Q of Checkpoint Therapeutics, Inc; 2. Based on my knowledge, this report does not contain any untrue statement of a
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 10, 2022	EX-32._2	Certification of Principal Financial Officer of Checkpoint Therapeutics, Inc. pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated November 10, 2022. Exhibit 32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Garrett Gray, Chief Financial Officer of Checkpoint Therapeutics, Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best
November 10, 2022	EX-31._1	Certification of Principal Executive Officer of Checkpoint Therapeutics, Inc. pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 10, 2022. Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, James F. Oliviero, certify that: 1. I have reviewed this report on Form 10-Q of Checkpoint Therapeutics, Inc; 2. Based on my knowledge, this report does not contain any untrue statement
November 9, 2022	EX-99.1	Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Successful completion of pre-BLA meetings in July Biologics license application (“BLA”) for both metastatic and locally advanced cutaneous squamous c Exhibit 99.1 Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Successful completion of pre-BLA meetings in July Biologics license application (“BLA”) for both metastatic and locally advanced cutaneous squamous cell carcinoma indications expected to be submitted by January 2023 Waltham, MA – November 8, 2022 – Checkpoint Therapeutics, Inc. (“Check
November 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 Checkpoint Thera UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commiss
November 4, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commiss
November 4, 2022	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Definitive Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Checkpoint Therapeutics, Inc. (Name
August 12, 2022	EX-99.1	Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 202 Exhibit 99.1 Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful completion of pre-BLA meetings in July 2022 Biologics license application (?BLA?) submission for both metastatic and locally
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3
August 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissi
July 21, 2022	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
July 21, 2022	EX-16.1	Letter from BDO USA, LLP, dated July 21, 2022. Exhibit 16.1 July 21, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on July 15, 2022, to be filed by our former client, Checkpoint Therapeutics, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours
June 16, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
June 16, 2022	EX-99.1	Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma Exhibit 99.1 Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma ? Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimab ? Previously met primary endpoint in patients with metastatic cSCC; BLA submission on track for later this y
June 15, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
May 12, 2022	EX-99.1	Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; Exhibit 99.1 Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022 Waltham, MA ? May 12, 2022 ? Checkpoint Therapeutics, Inc. (?Checkpoint?) (NASDAQ: CKPT), a clinical-stag
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents z ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 tm2213667d3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commi
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 tm2213667-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid
March 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissio
March 28, 2022	EX-99.1	Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Exhibit 99.1 Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Waltham, MA ? March 28, 2022 ? Checkpoint Therapeutics, Inc. (?Checkpoint?) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2021 and recent corporate highlights. James F. Oliviero, Presiden
March 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 28, 2022	EX-4.3	Description of Securities of Checkpoint Therapeutics, Inc. * ? Exhibit 4.3 DESCRIPTION OF SECURITIES When used herein, the terms ?we,? ?our,? and ?us? refer to Checkpoint Therapeutics, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of Checkpoint capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of our capital stock, you shou
January 25, 2022	EX-99.1	Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma Exhibit 99.1 Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma ? Study met primary endpoint with 47.4% objective response rate ? Safety and tolerability profile consistent with previously reported data ? Planned BLA submission on track for later this year ? Conference call to be held today,
January 25, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2022 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commiss
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commiss
November 4, 2021	EX-99.1	Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results Exhibit 99.1 Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results Waltham, MA ? November 4, 2021 ? Checkpoint Therapeutics, Inc. (?Checkpoint?) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2021. James F. Oliviero, President and Chief Executive Officer of Checkpoint, stated,
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 5, 2021	EX-99.1	Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results Exhibit 99.1 Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results New York, NY ? August 5, 2021 ? Checkpoint Therapeutics, Inc. (?Checkpoint?) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2021. James F. Oliviero, President and Chief Executive Officer of Checkpoint, stated, ?In
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commissio
June 11, 2021	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., filed as Exhibit 3.1 to Form 8-K filed on June 11, 2021 (File No. 001-38128) and incorporated herein by reference. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHECKPOINT THERAPEUTICS, INC. Checkpoint Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify as follows: FIRST: That the Corporation?s original Certificate of Incorporation was filed on
June 11, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2021 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
May 7, 2021	10-Q	Quarterly Report - FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 6, 2021	EX-99.1	Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Exhibit 99.1 Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights New York, NY ? May 6, 2021 ? Checkpoint Therapeutics, Inc. (?Checkpoint?) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2021, and recent corporate highlights. James F. Oliviero, Pres
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission F
April 30, 2021	DEF 14A	- DEF 14A TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 30, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 20, 2021	PRE 14A	- PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 12, 2021	10-K	Annual Report - FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 12, 2021	EX-4.3	Description of Securities of Checkpoint Therapeutics, Inc. * Exhibit 4.3 ? DESCRIPTION OF SECURITIES ? When used herein, the terms ?we,? ?our,? and ?us? refer to Checkpoint Therapeutics, Inc. ? DESCRIPTION OF CAPITAL STOCK ? The following description summarizes the material terms of Checkpoint capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of our capital stock, yo
March 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2021 Checkpoint Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38128 47-2568632 (State or Other Jurisdiction of Incorporation) (Commission
March 9, 2021	EX-99.1	Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights Exhibit 99.1 Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights New York, NY – March 9, 2021 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2020 and recent corporate highlights. James F. Oliviero, Presiden

CKPT / Checkpoint Therapeutics, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)